Most Read Articles
29 Mar 2020
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.
Pearl Toh, 12 Sep 2020
Early initiation of rhythm-control therapy led to a significantly reduced risk of major adverse cardiovascular (CV) outcomes compared with usual care (typically rate control) in patients with newly diagnosed atrial fibrillation (AF) at risk of stroke, reveals the EAST-AFNET 4* trial presented at ESC 2020.
01 Feb 2020
High-intensity statin therapy appears to be seeing increased use in patients with acute coronary syndrome and leads to better lipid control, according to a recent Thailand study.
18 Apr 2020
Statins appear to be useful as a primary prevention treatment in older adults with hypercholesterolaemia, reports a new meta-analysis.

What is the cut-off BP value for pregnant women at risk of masked hypertension?

21 Aug 2019

Having identified the prevalence and increased risk of masked hypertension in pregnant women, a recent study suggests that an office blood pressure (BP) of at least 125/75 mm Hg in the second half of gestation may be appropriate to indicate out-of-office measurements in high-risk pregnancies.

Of the 373 women (mean age, 30±7 years with 32±4 weeks of gestation), 69 (18.5 percent) developed pre-eclampsia or eclampsia. A stepwise increase was seen in the risk for pre-eclampsia or eclampsia through quartiles of systolic office BP (8.8 percent, 13.4 percent, 19.6 percent and 32.3 percent; p<0.001) and diastolic office BP (6.5 percent, 13.7 percent, 19.6 percent and 34.4 percent; p<0.001).

There was a significant increase in odds ratio (OR) through quartiles of systolic (p=0.004) and diastolic (p<0.001) office BP. The significance manifested more between the second and third quartile, with the cut-off point being 125/76 mm Hg.

The prevalence of white-coat hypertension was 3.8 percent and masked hypertension 24.7 percent. Using ambulatory BP monitoring (ABPM), 14 of 61 office hypertensive women were reclassified as having white-coat hypertension and 92 of 312 normotensive women as having masked hypertension.

Furthermore, there was a significant increase in OR for pre-eclampsia or eclampsia in women with masked hypertension.

Absolute risk for pre-eclampsia or eclampsia was comparable between women with office BP <125/75 mm Hg and those with normal ABPM (7.2 percent vs 7.1 percent).

This prospective cohort study included women in the second half of high-risk pregnancies. Participants had their office and ambulatory BP measured, and were divided according to quartiles of office BP and in normotension, white-coat hypertension, masked hypertension and sustained hypertension. The investigators then estimated the risks for pre-eclampsia or eclampsia for each category.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Mar 2020
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.
Pearl Toh, 12 Sep 2020
Early initiation of rhythm-control therapy led to a significantly reduced risk of major adverse cardiovascular (CV) outcomes compared with usual care (typically rate control) in patients with newly diagnosed atrial fibrillation (AF) at risk of stroke, reveals the EAST-AFNET 4* trial presented at ESC 2020.
01 Feb 2020
High-intensity statin therapy appears to be seeing increased use in patients with acute coronary syndrome and leads to better lipid control, according to a recent Thailand study.
18 Apr 2020
Statins appear to be useful as a primary prevention treatment in older adults with hypercholesterolaemia, reports a new meta-analysis.